DARZALEX FASPRO^® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma¹DARZALEX FASPRO^® monotherapy is now approved in high-risk smoldering multiple myeloma¹

Leadership in the treatment of newly diagnosed multiple myeloma

Expand your frontline frontiers with
DARZALEX^® and DARZALEX FASPRO^®

Explore a
Triplet

Regimen with DARZALEX^®

(daratumumab)

MAIA: DRd in Transplant-Ineligible NDMM Exploratory Subgroup Analyses

Discover a
Quad

Regimen with DARZALEX FASPRO^®

(daratumumab and hyaluronidase-fihj)

PERSEUS: DVRd in Transplant-
Eligible NDMM

MAIA: Post hoc
analyses of
Treatment Duration

with DARZALEX^® + Rd

See Post Hoc Analyses